Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.950-5.050 for the period, compared to the consensus EPS estimate of 4.740. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Analyst Ratings Changes

Several equities analysts have commented on GMED shares. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler lowered their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Needham & Company LLC upped their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. UBS Group began coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target on the stock. Finally, Stifel Nicolaus decreased their price objective on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $101.77.

Globus Medical Price Performance

NYSE GMED traded up $0.54 during trading on Friday, reaching $81.62. 1,646,375 shares of the company’s stock traded hands, compared to its average volume of 1,488,296. The firm has a market cap of $11.08 billion, a price-to-earnings ratio of 19.04, a price-to-earnings-growth ratio of 1.66 and a beta of 0.95. The company’s 50 day simple moving average is $79.33 and its two-hundred day simple moving average is $85.25. Globus Medical has a 12-month low of $54.15 and a 12-month high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The firm had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the firm earned $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Research analysts expect that Globus Medical will post 4.74 earnings per share for the current fiscal year.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 18.38% of the company’s stock.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Strong second-quarter results: Globus Medical reported adjusted EPS of $1.34, well above analyst estimates of approximately $1.10–$1.12 and up from $0.86 a year earlier. Revenue rose 5.9% year over year to $789.6 million, also exceeding expectations of about $782.9 million. Globus Medical Reports Second Quarter 2026 Results
• Positive Sentiment: Raised earnings guidance: Management forecast fiscal 2026 EPS of $4.95–$5.05, above the approximately $4.74 analyst consensus. Revenue guidance of roughly $3.2 billion was broadly in line with expectations, indicating that the upside is primarily driven by profitability and earnings power. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Constructive analyst views: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings potential and continued research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Wells Fargo lowered its price target from $103 to $99 but retained an Overweight rating. The reduced target reflects somewhat more cautious valuation expectations, although it still implies substantial upside from recent trading levels. Benzinga analyst update
• Neutral Sentiment: Investors continue to monitor tariff and inflation pressures, hospital-spending conditions and the pace of spine-market growth, which could affect future demand and margins.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Advisory Services Network LLC acquired a new stake in Globus Medical in the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares in the last quarter. Headlands Technologies LLC increased its position in Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after buying an additional 631 shares in the last quarter. Finally, Hollencrest Capital Management purchased a new stake in Globus Medical in the fourth quarter valued at about $51,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.